Ovid Therapeutics Inc
NASDAQ:OVID

Watchlist Manager
Ovid Therapeutics Inc Logo
Ovid Therapeutics Inc
NASDAQ:OVID
Watchlist
Price: 1.53 USD -1.29% Market Closed
Market Cap: $109m

Operating Margin

-618.3%
Current
Improving
by 14 067.6%
vs 3-y average of -14 685.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-618.3%
=
Operating Income
$-40.9m
/
Revenue
$6.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-618.3%
=
Operating Income
$-40.9m
/
Revenue
$6.6m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Ovid Therapeutics Inc
NASDAQ:OVID
110.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 14 112 companies
9th percentile
-618.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Ovid Therapeutics Inc
Glance View

Market Cap
109m USD
Industry
Biotechnology

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2017-05-05. The firm is focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. The Company’s programs include OV329 (GABA aminotransferase inhibitor), OV350, OV882, and OV815 and OV825. OV329 (GABA aminotransferase inhibitor) is a next-generation GABA aminotransferase inhibitor being developed for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV329 functions by substantially reducing the activity of GABA aminotransferase (GABA-AT), a key enzyme responsible for the degradation of the brain’s major inhibitory neurotransmitter, GABA. OV350 is a small molecule that directly activates the KCC2 transporter, which is an important channel in seizure control. OV882, which is a short hairpin RNA (shRNA-551) for Angelman syndrome. OV815, which is a genetic therapy approach for KIF1A-associated neurological disorders.

OVID Intrinsic Value
0.08 USD
Overvaluation 95%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-618.3%
=
Operating Income
$-40.9m
/
Revenue
$6.6m
What is Ovid Therapeutics Inc's current Operating Margin?

The current Operating Margin for Ovid Therapeutics Inc is -618.3%, which is above its 3-year median of -14 685.9%.

How has Operating Margin changed over time?

Over the last 3 years, Ovid Therapeutics Inc’s Operating Margin has increased from -4 985.7% to -618.3%. During this period, it reached a low of -54 200% on Mar 31, 2023 and a high of -618.3% on Sep 30, 2025.

Back to Top